E. Ramsay Camp
YOU?
Author Swipe
View article: Supplementary Data 2 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 2 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Supplementary Data
View article: Supplementary Data 1 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 1 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Supplementary methods, figures, and tables.
View article: Supplementary Data 3 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Supplementary Data 3 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Clinical Trial Protocol
View article: Data from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Data from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma Open
Purpose:Immune checkpoint inhibitors (ICI) have limited efficacy in pleural mesothelioma. We investigated the role of Dickkopf WNT signaling pathway inhibitor 3 (DKK3) in overcoming treatment resistance.Patients and Methods:We performed pr…
View article: Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition
Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition Open
SNAI1/SPHK2 signaling mediates cancer stemness and 5FU resistance, implicating S1P as a therapeutic target for CRC. The S1P inhibitor ABC294640 holds potential as a therapeutic agent to target CSCs in therapy refractory CRC.
View article: Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma Open
Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer that arises in a background of chronic hepatic injury. Metabolic syndrome-associated fatty liver disease (MAFLD) and its severe form, nonalcoholic steatohepatitis (NASH),…
View article: Sphingosine-1-Phosphate Inhibition Increases Endoplasmic Reticulum Stress to Enhance Oxaliplatin Sensitivity in Pancreatic Cancer
Sphingosine-1-Phosphate Inhibition Increases Endoplasmic Reticulum Stress to Enhance Oxaliplatin Sensitivity in Pancreatic Cancer Open
Our evidence suggests that sphingolipid metabolism is dysregulated in PDAC. Furthermore, S1P inhibition can sensitize PDAC to Oxa therapy through increasing ER stress and can potentiate ICD induction. This highlights a potential therapeuti…
View article: Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma Open
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvir…
View article: Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer
Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer Open
Introduction Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with limited response to both chemotherapy and immunotherapy. Pre-treatment tumor features within the tumor immune microenvironment (TiME) may influence treatment respons…
View article: Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model
Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model Open
The use of humanized mouse models for oncology is rapidly expanding. Autologous patient-derived systems are particularly attractive as they can model the human cancer’s heterogeneity and immune microenvironment. In this study, we developed…
View article: Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants Open
RAS guanosine triphosphatases (GTPases) are mutated in nearly 20% of human tumors, making them an attractive therapeutic target. Following our discovery that nucleotide-free RAS (apo RAS) regulates cell signaling, we selectively target thi…
View article: Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans
Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans Open
Background African Americans (AAs) have higher colorectal cancer (CRC) incidence and mortality rate than Caucasian Americans (CAs). Recent studies suggest that immune responses within CRCs contribute to the disparities. If racially distinc…
View article: Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities
Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities Open
Background Disparities in colon cancer (CC) outcomes may be due to a more aggressive phenotype in African American patients in the setting of a decreased tumor immunity, though the precise mechanism for this result has not been well elucid…
View article: Differential Immune Signatures in the Tumor Microenvironment are Associated with Colorectal Cancer Racial Disparities: A Cohort Study of Biorepository Data
Differential Immune Signatures in the Tumor Microenvironment are Associated with Colorectal Cancer Racial Disparities: A Cohort Study of Biorepository Data Open
Background: Disparities in colorectal cancer outcomes may be due to a more aggressive phenotype in African American patients in the setting of a decreased tumor immunity, though the precise mechanism for this result has not been well eluci…
View article: Modeling rectal cancer to advance neoadjuvant precision therapy
Modeling rectal cancer to advance neoadjuvant precision therapy Open
Progress in rectal cancer therapy has been hindered by the lack of effective disease‐specific preclinical models that account for the unique molecular profile and biology of rectal cancer. Thus, we developed complementary patient‐derived x…
View article: SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors Open
We identified unique molecular mechanisms of resistance to CDK4/6 inhibitors, an area of intense biomedical investigation.
View article: Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy Open
Pancreatic adenocarcinoma (PDAC) remains a formidable disease that needs improved therapeutic strategies. Even though immunotherapy has revolutionized treatment for various solid tumor types, it remains largely ineffective in treating indi…